Bausch & Lomb Corp
BLCONYSEHealthcare · Ophthalmic Goods · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.10B | $4.79B | $4.15B | $3.77B | $3.77B | $3.41B |
| Operating income | $113.0M | $162.0M | $130.0M | $207.0M | $329.0M | $260.0M |
| Net income | −$360.0M | −$317.0M | −$260.0M | $6.0M | $182.0M | −$18.0M |
| Total assets | $14.02B | $13.47B | $13.44B | $11.14B | $10.82B | — |
| Total liabilities | $7.50B | $6.92B | $6.52B | $4.04B | $1.42B | — |
| Equity | $6.45B | $6.47B | $6.85B | $7.03B | $9.33B | $9.99B |
| EPS (diluted) | $-1.02 | $-0.90 | $-0.74 | $0.02 | $0.52 | $-0.05 |
| Shares out. | 352.5M | 351.0M | 350.0M | 350.0M | 350.0M | 350.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 2.2%
- Net margin
- −7.1%
- Return on equity
- −5.6%
- Return on assets
- −2.6%
- Return on capital (ROCE)
- 0.9%
- Liabilities / assets
- 53.5%
- Debt / equity
- 1.16×
- Book value / share
- $18.29
- Revenue growth (YoY)
- 6.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 1.23grey zone
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 warning● 4 good- Reported a net loss
- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Von Eschenbach Andrew C.Director | May 26, 2026 | Grant | 15,842 | $15.78 |
| Ross Thomas W. Sr.Director | May 26, 2026 | Grant | 15,842 | $15.78 |
| Robertson Russel CDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Paulson JohnDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Ling KarenDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Kavanagh Sarah BDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Collis Steven HDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Bernier Nathalie D.Director | May 26, 2026 | Grant | 15,842 | $15.78 |
| Alfonso EduardoDirector | May 26, 2026 | Grant | 15,842 | $15.78 |
| Saunders Brent LOfficer — Chairman of the Board and CEO | May 22, 2026 | Tax withholding | 2,886 | $15.92 |
| Eldessouky SamOfficer — EVP and CFO | May 5, 2026 | Tax withholding | 63,938 | $16.00 |
| Hashad YehiaOfficer — EVP of R&D and CMO | May 5, 2026 | Tax withholding | 13,664 | $16.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 2.5M | 4.7 | -30.7% |
| Apr 30, 2026 | 3.6M | 7.5 | -2.6% |
| Apr 15, 2026 | 3.7M | 10.9 | +2.7% |
| Mar 31, 2026 | 3.6M | 7.7 | -9.8% |
| Mar 13, 2026 | 4.0M | 9.5 | +50.7% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 20, 2026
- Results of operationsApr 29, 2026
- Results of operationsFeb 18, 2026
- Entered a material agreement · New financial obligation · Other material eventJan 2, 2026
- Director / officer changeDec 17, 2025
- Other material eventDec 12, 2025
- Regulation FD disclosureNov 13, 2025
- Results of operationsOct 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SDJun 1, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 28, 2026
- 4PRIMARY DOCUMENTMay 26, 2026
- 8-KMay 20, 2026
- 4PRIMARY DOCUMENTMay 7, 2026
- 4PRIMARY DOCUMENTMay 7, 2026
- 4PRIMARY DOCUMENTMay 7, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.